Avacta Group (LSE:AVCT) CEO Alastair Smith , CFO Tony Gardiner and Head of Operations Neil Bell present a broad overview of the business, which produces lateral flow tests for Covid-19, and answer a range of investor questions. The event, held on 21June 2021, is brought to you by our friends at Investor Meet Company.
34 :20 - Q&A
About the company:
Avacta Group PLC is a UK-based biotechnology company catering to the healthcare sector. It develops medical diagnostic products such as reagents and arrays which are helpful in drug discovery. It offers products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and preCISION tumor-targeted chemotherapy. It operates in the United Kingdom, Rest of Europe, Asia, and North America.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.